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nloaded froLymphatic filariasis and onchocerciasis are two important neglected tropical diseases (NTDs) that cause severe dis-
ability. Control efforts are hindered by the lack of a safe macrofilaricidal drug. Targeting the Wolbachia bacterial en-
dosymbionts in these parasites with doxycycline leads to a macrofilaricidal outcome, but protracted treatment
regimens and contraindications restrict its widespread implementation. The Anti-Wolbachia consortium aims to de-
velop improved anti-Wolbachia drugs to overcome these barriers. We describe the first screening of a large, diverse
compound library againstWolbachia. This whole-organism screen, streamlined to reduce bottlenecks, produced a hit
rateof 0.5%. Chemoinformatic analysis of the top50hits led to the identificationof six structurally diverse chemotypes,
the disclosure of which could offer interesting avenues of investigation to other researchers active in this field. An
example of hit-to-lead optimization is described to further demonstrate the potential of developing these high-quality
hit series as safe, efficacious, and selective anti-Wolbachia macrofilaricides.m
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TheWolbachia endosymbiont of filarial nematodes is a validated chemo-
therapeutic target for the treatment of lymphatic filariasis (1–7) and
onchocerciasis (8–11). These debilitating neglected tropical diseases
(NTDs) affect more than 150 million people, and although control
programs have made great strides in reducing prevalence in endemic
countries (12, 13), progress toward elimination is hampered by the
lack of a safe drug capable of killing adult worms (14, 15). Targeting
the Wolbachia bacteria within filarial nematodes using antibiotics
offers the desired macrofilaricidal activity because the nematodes rely
on their endosymbionts for their development, fecundity, and survival
(16). Furthermore, an anti-Wolbachiamode of action provides an ex-
cellent safety profile due to the protracted death of adult worms. Such
amechanism has no effect on theWolbachia-negative Loa loa parasites
that can cause serious adverse events in some coinfected individuals
treated with the standard anti-filarial drug ivermectin (17). Doxycycline
has been proven effective as an anti-Wolbachia macrofilaricidal agent,
but its long course of treatment (4 to 6weeks) and contraindications in
pregnancy and young children restrict its widespread use. The Anti-
Wolbachia (A∙WOL) consortium was formed with the aim of finding
a new anti-Wolbachia treatment with a shorter treatment duration
(ideally less than 7 days) and utility in pregnant women and children
(18, 19).
The A∙WOL consortium has a drug discovery and development
pipeline that has been refined over time to optimize the translation
of compounds from preclinical models to the clinic (18). The initial
step in the pipeline was to screen compounds using a cell-based screen
incorporating a Wolbachia-infected Aedes albopictus cell line [C6/36
(wAlbB)]. This validated screen was used to screen the complete hu-
man pharmacopoeia (20) and a variety of focused antimicrobial li-
braries (18). Although hits have been discovered from these screens,some of which have progressed further down the pipeline, the diver-
sity in the chemical space covered thus far has been fairly limited. To
explore greater chemical diversity, with the aim of driving the discov-
ery of novel compounds with activity againstWolbachia, we chemoin-
formatically selected 10,000 compounds from the BioFocus SoftFocus
small-molecule libraries. The rationale and successes of the SoftFocus
screening approach have been described elsewhere (21), whereas hits
from these libraries against malaria (22–28) and tuberculosis (29) have
been identified and published previously. Here, we describe the first
large diverse screen to be conducted against a validated chemotherapeutic
target of filarial nematodes and report on six structurally diverse active
chemotypes, one of which was optimized to provide a quality lead com-
poundwith a potential for further refinement toward a clinical candidate.RESULTS
Assay development
To optimize our existing validated screening assay (20) for increasing
throughput and capacity, we made a number of adaptations that are
detailed in Supplementary Materials and Methods. Briefly, all aspects
of the screening workflow were scrutinized in terms of scalability by
conducting pilot experiments using a small selection of BioFocus com-
pound plates. The main improvements made were to the cell toxicity
readout and the quantitative polymerase chain reaction (qPCR) re-
agents, both ofwhich reduced the screening timewithout affecting assay
robustness. All amendments to the published protocol were validated
using the analysis of Z and Z′ statistical parameters, and the subsequent
primary screening of the library was completed in less than 1 year, an
order of magnitude increase in our screening efficiency.
Hits from primary screen
The 10,000 compounds from the BioFocus SoftFocus libraries were
screened againstWolbachiausing the validatedA∙WOLcell-based assay
(Fig. 1). We incubated C6/36 (wAlbB) cells with compounds for 9 days
and performed qPCR on a Wolbachia single copy gene to analyze re-
ductions inWolbachia load. Doxycycline and vehicle [dimethyl sulfoxide1 of 10
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 (DMSO)] were used as internal controls on each plate and direct
cellular toxicity was assessed through the scoring of confluence using
microscopy (Fig. 1). Hits were defined as those compounds that re-
duced theWolbachia 16S copy number by 1 log or greater (≥1 log drop),
without evidence of cytotoxicity to theA. albopictus cell line (a reduction
in cell confluence of <50%, as scored by microscopy). These stringent
criteria were implemented to best optimize our ability to triage hits for
follow-up, given the size of the library and the throughput of our assay.
Initial screening using a concentration of 2.5 mg/ml resulted in 174 pri-
mary hits (Fig. 2). Overall, the proportion of compounds producing direct
toxicity to the cell line was 3.6%. Hits were rescreened at the same con-
centration, resulting in 112 reconfirmed hits (confirmation rate of 64%).
Hit validation
Of the 112 confirmed hits, 71 were available to buy as dry stocks and to
be used in the validation process. As the original compound plates were
provided as 10-mg/ml stocks, the final molar concentrations used in the
primary screen fell within the range of 3.97 to 14.75 mM,with amean ofJohnston et al., Sci. Adv. 2017;3 : eaao1551 27 September 20176.65 mMand amedian of 6.68 mM.We conducted the validation testing
using a standard concentration of 5 mMon two separate occasions. Tox-
icity was quantified on replicate plates using the CellTiter-Glo assay.
Hits were confirmed as those compounds that reduced the Wolbachia
16S copy number by 0.5 log or greater while maintaining a CellTiter-
Glo readout of 70% or greater than the vehicle-treated control wells. In
this way, 50 hits were identified and progressed into chemoinformatic
analysis (Fig. 2).
Chemoinformatic analysis
Chemoinformatic techniques can assist the drug discovery process by
viewing, organizing, and understanding relationships between
measured biological data and molecular properties (30) to make
quicker, more accurate decisions. Using these chemoinformatics tech-
niques, the 50 validated hits were profiled using the parameters listed in
table S1 to identify the optimal chemotypes to enter a hit-to-lead phase.
An ideal chemotype chosen for hit-to-lead development would be po-
tent, display some initial structure-activity relationship (SAR) andData analysis
Wolbachia 16S log reduction 
calculated using in plate DMSO 
controls on plates achieving Z' ≥ 0.4
Assay preparation
Daughter plates made from stock plates
Dilution plates created on day 0
Medium 
toxicity
High 
toxicity
Assay set up and run
Wolbachia infected cells seeded onto plates
Test compounds added to cells in triplicate
DMSO & doxycycline controls added in triplicate
Plates incubated at 26 °C for 9 days
Day 9
Toxicity 
scored by
microscopy
As control
Lysis buffer added to cells
DNA extraction
DNA extracted using 96-well extraction protocol
Quality control
Z' statistical analysis conducted per plate using DMSO 
and doxycycline controls (assays with Z' < 0.4 repeated)
qPCR
qPCR conducted in 384-well format
Targets the 16S rRNA gene of Wolbachia
Readout is 16S copy number
Confirmation 
screenLog drop    1 = HIT
Fig. 1. Primary screening workflow. The graphics and text demonstrate a typical screening run involving a batch of four compound plates (216 compounds), with
each plate representing one color. Compounds, as well as vehicle (DMSO) and doxycycline controls (shown as hatched areas), were used in triplicate. Following a 9-day
incubation, plates were scored for cytotoxicity using microscopy, followed by cell lysis and DNA extraction. qPCR targeting the 16S rRNA gene of Wolbachia was
conducted, and data were subjected to quality control using Z′ statistical analysis. Wolbachia 16S log reductions (“log drop”) were calculated per compound using
in-plate DMSO controls, and those that were considered hits moved into confirmation screening. A more detailed description of this workflow is presented in Sup-
plementary Materials and Methods.2 of 10
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 ideally be lead/drug-like in pharmacokinetic, physiochemical, and
structural parameters. Full details of the filtering procedure are included
in Supplementary Materials and Methods.
Cluster analysis
Cluster analysis on the 50 hit compounds using molecular fingerprints
(31) and their representation within chemical space using principal
component analysis (PCA) (32) revealed six main clusters, with the
other compounds being identified as singletons (Fig. 3). This clustering
in chemical spacewas confirmedby inspection of themaximal common
substructure of the clustered hits.
Following approaches from the analysis performed on the out-
puts from the antimalarial high-throughput screening completedJohnston et al., Sci. Adv. 2017;3 : eaao1551 27 September 2017by GlaxoSmithKline (33), we have used a procedure to assign a “se-
lection score” to each compound, with the maximum score being 30.
We aimed to identify the best compounds and series, and to this end,
we focused on compound potency, lipophilicity, number of com-
pounds in the cluster, and molecular weight (see Supplementary
Materials and Methods for details on how the scores were assigned
to each compound’s properties). This analysis revealed that the six
clusters identified all contained multiple compounds above our
score threshold of 15 (Fig. 3).
The chemically distinct clusters displayed an initial SAR (that is,
they were not singletons) and hadmicromolar to nanomolar potency
and acceptable lipophilicity with low molecular weights. The six hit
series are summarized in Table 1 and include ThienopyrimidinesCompounds Hits
Confirmed 
hits
Validated 
hits
10,000 174 112 50 6
● Wolbachia cell-based assay
● Single point testing 
● 2.5 µg/ml
● 9 day assay, qPCR readout
● Toxicity: microscopy
Primary screening
● Wolbachia cell-based assay
● Single point testing 
● 2.5 µg/ml
● 9 day assay, qPCR readout
● Toxicity: microscopy
Hit confirmation
● Wolbachia cell-based assay
● 71 dry stocks tested
● 5 µM
● 9 day assay, qPCR readout
● Toxicity: CellTiter-Glo
Hit validation
● Pareto optimization
   ● Measured properties
   ● SAR
   ● Cal. ADMET properties
● Cluster analysis
Chemoinformatics
Chemically 
diverse 
hit 
series
Fig. 2. Screening cascade from primary screening to identification of lead series. Circles show the numbers of compounds resulting from each step in the pipeline
(shown in boxes).Fig. 3. Chemical space depiction of the 50 validated hits. The first two principle components (PC1 and PC2) together account for 36.9% of the overall variance of the
chemistry of these 50 compounds using molecular fingerprints (PathFp). The six distinct chemotypes show clustering in chemical space. The size of each data point is
proportional to the total score for that compound (maximum score, 30).3 of 10
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 (series 1), Imidazo[4,5-c]pyridines (series 2), Oxazepinones (series
3), Imidazo[1,2-a]pyridines (series 4), Pyrrolopyridines (series 5),
andOxazole imidazolidinones (series 6). Pareto analysis was performed
to identify compound clusters with the best overall profile (34), consid-
ering the compounds’ potency, in silico toxicity, and ADME (absorption,
distribution, metabolism, and excretion) properties. Pareto optimization
allows simultaneous optimization of many properties (for example,Johnston et al., Sci. Adv. 2017;3 : eaao1551 27 September 2017biological and physiochemical) through multiparameter optimization
(35). This approach allows trade-offs between sometimes competing ob-
jectives to be made, resulting in a better compound profile overall. This
approach is in contrast to historical drug discovery that focused on po-
tency and led tomany late-stage failures due to poorADMET(absorption,
distribution, metabolism, excretion, and toxicity) and/or physiochemical
properties (36). Our analysis ranked all six series equally highly, giving usTable 1. Cluster analysis of the 50 hits together with the core structures of the six clusters identified.
Cluster no., name and generic structure  Number of 
active/inactive 
compounds 
Average log drop of 
actives ± SD  
1. Thienopyrimidine 
 
11/143 0.73 ± 0.41 
2. Imidazo[4,5-c]pyridine 
 
5/202 0.89 ± 0.40 
3. Oxazepinone 
 
7/329 0.96 ± 0.46 
4. Imidazo[1,2-a]pyridine 
 
6/849 0.94 ± 0.35 
5. Pyrrolopyridine 
 
14/371 0.57 ± 0.29 
6. Oxazole imidazolidinone 
 
2/126 1.50 ± 0.04 4 of 10
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 confidence in the quality of the hit series for subsequent lead optimization
(see Supplementary Materials and Methods).
During the screening and analysis of this compound set, we
were in the process of developing a high-content imaging (Operetta,
PerkinElmer) assay (37). This assay enables dose-response studies to
be conducted and median effective concentration (EC50) values to be
estimated (data not obtainable using the qPCR technique). We used
this Operetta-based assay to titrate the activity of selected hits and
generate EC50 values. The EC50 range produced by the six hit che-
motypes was 112 to 5681 nM (Table 2). At the same time, some of
the selected hits were also assessed for their drug metabolism and
pharmacokinetic (DMPK) properties, including lipophilicity, aque-
ous solubility, and metabolic stability in vitro.
In the Thienopyrimidine series (series 1), representative compound
1has good potency, low logD, and amolecular weight of 358. Themeta-
bolic stability is poor, but this could be rectified by the manipulation of
metabolically susceptible groups within the starting point (dimethoxy
ring system and benzylic linker). An additional attractive feature of this
template is the modular nature of the chemistry for template syntheses,
where simple SNAr reactions of 2,4-dichloro thienopyridine with suit-
able aromatic and aliphatic amines can be used to provide an array of
diversely functionalized analogs.
The Imidazo[4,5-c]pyridine series representative compound 2 had
all-around excellent physicochemical properties, metabolic stability,
and acceptable solubility.With the lowestmolecular weight of the entire
series, thismolecule looks attractive for hit-to-lead optimization focused
on potency. Chemistry for the synthesis of analogs in this series is
straightforward, allowing manipulation of the 2- and 4- positions of
the imidazo[4,5-c]pyridine core. In the Oxazepinone series, representa-
tive compound 3 has good potency and physicochemical properties.
Metabolic stability appears to be the key parameter for optimizationJohnston et al., Sci. Adv. 2017;3 : eaao1551 27 September 2017in this hit series, and although the logDwasmeasured at 2.8, the overall
solubility of this representative was poor (2 mM).
The most potent hit 4, an imidazo[1,2-a]pyridine, has a selection
score of 26 and, as seen for series representative 3, has weak metabolic
stability. Improving the metabolic stability will be the primary hit opti-
mization challenge for this series. In silico prediction of metabolic weak
points in this hit compound identified the A- and D-rings and the ben-
zylic linkers, so medicinal chemistry focused on mitigation of oxidative
attack at these positions should be considered. In the remaining two hit
series, although the pyrrolopyridine analog 5 and oxazole imidazolidi-
none 6 had similar selection scores, series 5 was considered to be supe-
rior based on microsomal stability, measured solubility, and low logD.
As for the other series, modular chemistry elaboration of 5 is possible
through SNAr reactions (of an appropriate 6-chloro analog) for diver-
sifying the left-hand side of the hit molecule (6-position of the pyrrolo-
pyridine core) and through the Suzuki reaction for elaboration of the
right-hand side (2-position of the pyrrolopyridine core).
Hit to lead
Given the potency and synthetic tractability of series 1 and the identi-
fication of the metabolic weak spots, we initiated medicinal chemistry
focused on the optimization of the DMPK properties (while maintain-
ing or improving the anti-Wolbachia activity) to establish early leads for
further development. Upon inspection of molecule 1, the electron-rich
nature of the dimethoxy aromatic ring, the benzylic linker and the 6-
position of the thieno[3,2-d]pyrimidine-2,4-diamine were considered
as potential points of P450-mediated oxidative metabolism. In addition
to addressing the metabolic stability of this hit, it was also considered
necessary to reduce the lipophilicity and themolecular weight in the hit-
to-lead optimization phase. Through iterative rounds of medicinal
chemistry optimization, we were able to show that by incorporating a o
n
 Septem
ber 28, 2017
g.org/Table 2. Measured EC50 value and DMPK properties for representatives from six identified hit clusters. MW, molecular weight.
Representative structure 
      
BioFocus code 790_4020_0354
 
729_2047_0052_ 
0263 853_6001_0174 
310_5632_5837_ 
8158_0236 809_2679_5837_0109 894_7990_4021 
Chemical class/series 
number  Thienopyrimidine (1)
 
Imidazo[4,5-
c]pyridine (2) 
Oxazepinone (3)
 
Imidazo[1,2-
a]pyridine (4) 
Pyrrolopyridine (5)
 
Oxazole 
imidazolidinone (6) 
M. W. (g/mol) 358.5 292.4 407.5 448.5 347.4 458.4 
EC50 ± SD (nM)  328 ± 55 847 ± 12 670 ± 9 112 ± 19 353 ± 77 5681 ± 756 
LogD7.4 3.7 4.1 2.8 4.1 3.2 3.9 
Solubility (µM)* 113 83 2 11 408 4 
Measured human* 
microsome clearance 
(µl/min/mg) 
112
 
17.5
 
98
 
300
 
61
 
90
 
Rat hepatocytes clearance* 
(µl/min/1×106  cells)  300
 
21
 
102
 
300
 
21
 
109
 
Selection score†  27 24 26 26 25 24 
*Acceptable and desired ranges of measured parameters: EC50, <1000 nM (acceptable) and <100 nM (desired); logD7.4, <5 (acceptable) and <3 (desired); aque-
ous solubility, >20 mM (acceptable) and >50 mM (desired); human microsome and rat hepatocytes clearance, <70 ml min−1 mg−1 and <70 ml min−1 per 1 × 106cells (acceptable) and <20 ml min−1 mg−1 and <20 ml min−1 per 1 × 106 cells (desired). †Note that selection score was based solely on potency, logP, the
number of compounds in cluster, and molecular weight, as discussed in the main text.5 of 10
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 strong electron-withdrawing group in the 4-position of the benzylic side
chain, we could significantly improve the anti-Wolbachia activity and
metabolic stability. AWB124 was established as an early lead in the
Thienopyrimidine series, with relatively lowmolecular weight, excellent
potency, significantly improved DMPK properties, and good safety
window (Fig. 4). Further optimization was focused on the trifluorophe-
nyl ring side chain of AWB124 and modification/truncation of the
side chain at the 2-position of the thienopyrimidine ring. We found
that the 2-positionN-isopropylamine is not essential for anti-Wolbachia
activity, and by conversion of the trifluorophenyl ring into the
corresponding pyridyl ring system, the resulting molecule AWG117
was obtained. AWG117 expressed nanomolar anti-Wolbachia activity,
had significantly lower lipophilicity (logD7.4 = 2.6) compared to
AWB124 (logD7.4 = 4.5), and hadmuch improvedmicrosomal stability
and aqueous solubility. Cytotoxicity evaluation in THP-1 cells indi-
cated low cytotoxicity with a very good in vitro therapeutic index.
This lead compound is now primed for additional lead optimization
toward a candidate molecule.DISCUSSION
Here, we describe the first large-scale diversity screen againstWolbachia,
a validated target of the filarial nematodes responsible for the NTDs
lymphatic filariasis and onchocerciasis. We identified and validated
50 hits that could be clustered into six unique chemotypes with the
potential for onward drug development. This is the first diversity screen
ever performed against these NTDs and one that has already delivered
chemical novelty and diversity into what is currently a relatively narrow
and mechanistically restricted drug portfolio.
The drug discovery landscape for helminth diseases in general has
been moribund for a long time, with most drugs for nematode infec-Johnston et al., Sci. Adv. 2017;3 : eaao1551 27 September 2017tions of humans coming via the much less neglected veterinary market
(38). There is an urgent need for an effective macrofilaricide to treat
lymphatic filariasis and onchocerciasis, and proof-of-concept clinical
trials (1–11) have demonstrated that targetingWolbachia provides this
action with an excellent safety profile. The success of the A∙WOL ap-
proach has been validated because compounds discovered as active in
the primary cell-based screen (20) have progressed through the A∙WOL
screening funnel and a selection (including minocycline, rifampicin,
and the tylosin analog TylAMac) have been either tested in clinical trials
(39, 40) or selected for clinical candidate development ( www.dndi.org/
diseases-projects/portfolio/macro-filaricide-2/). These repurposed anti-
infective compoundswere sourcedeither fromcurrently registereddrugs on
the market (20) or from focused anti-infective libraries provided by phar-
maceutical companies working on drug discovery programs for other
pathogens (18, 19). Therefore, the six structurally diverse chemotypes de-
scribed here represent the first foray into the unknown for A∙WOL drug
discovery and, hence, offer exciting avenues of drug discovery research.
We have conducted the first large-scale diverse screening campaign
againstWolbachia and validated 50 hits. A range of molecular proper-
ties were assessed to see whether they correlated with delivering the one
log drop in bacterial load desired of a hit compound. Analysis of mo-
lecular weight, CLogP, number of rotatable bonds, number of hydrogen
bond donors and acceptors, and polar surface area for both the 9950
inactive molecules and the 50 validated hits demonstrated that there
is no clear trend for any of these molecular parameters in determining
biological activity (fig. S1), thereby underscoring the benefits of exam-
ining diverse compound sets, with a broad range of molecular charac-
teristics, against phenotype in the search for novel active compounds.
Through chemoinformatic and cluster analysis, six novel chemo-
types were identified and assessed for various drug-related properties
in silico. In addition, the most potent representatives determined byFig. 4. Progression of series 1 thienopyrimidine from screening hit to early lead.6 of 10
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 their measured EC50 values from each series were also assessed for
their DMPK properties in vitro to evaluate their suitability for further
development in the pipeline. We have demonstrated the tractability of
one of the series by performing hit-to-lead optimization through the
use of well-considered medicinal chemistry optimization strategies
focused on enhancing metabolic stability.
Although the top hits exemplified inTable 2 are not presented in any
previously published literature, the core of five series (series 1 to 5) be-
longs to a group of privileged pharmacophores that can target multiple
biologically significant proteins, which are relevant to a range of dis-
eases. Thienopyrimidines (series 1), imidazo[4,5-c]pyridines (series 2),
oxazepinones (series 3), and pyrrolopyridines (series 5) have been iden-
tified as inhibitors of a range of kinases (41–43) ormodulators of various
heterotrimeric guanine nucleotide–binding protein–coupled receptor
(GPCR) proteins (44, 45) in the literature. In addition, noticeably, thie-
nopyrimidines (series 1) have been reported to have antimalarial activ-
ities (46), and the oxazepinone core in series 3 and the imidazo[1,2-a]
pyridine core in series 4 have appeared in the experimental drugs TAK-
475 (squalene synthase inhibitor) (47) and Q203 (antituberculosis
agent) (48), respectively. However, the substituent patterns of the hit
series identified in this campaign are distinctly different from any
known molecules, and we do not speculate that the protein targets of
these anti-Wolbachia hits are related to any of those reported in the lit-
erature. Oxazole imidazolidinones (series 6) have very limited represen-
tation in the literature and can be considered as a completely novel
chemotype for anti-infective activity.
All the available evidence indicates that the six novel chemotypes
presented here have great potential to be developed further as anti-
Wolbachiamacrofilaricidal drugs for the treatment of lymphatic fila-
riasis and onchocerciasis. The disclosure of these starting points
should also enable other researchers active in this field to initiate their
ownmedicinal chemistry optimization programs akin to those seen in
the malaria and tuberculosis drug discovery fields (49, 50). o
n
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Compounds
The collection of 10,000 compounds was provided by BioFocus. Al-
thoughmost of the compounds presentwere derived from the SoftFocus
libraries, some came from ThemePair (approximately 900), FieldFocus
(approximately 1000), and other (approximately 1200) libraries. Over-
all, the collection encompassed kinase, ion channel, GPCR, protease,
protein-protein interaction, helix mimetic, and nucleoside-targeted
libraries. Compounds were provided as DMSO stocks in 96-well
compound storage plates at a concentration of 10 mg ml−1 and were
stored at −20°C until use. Dry stocks of hits were purchased from
eMolecules.
The synthesis of AWB124 and AWG117 are described in Supple-
mentaryMaterial andMethods and schemes S1 and S2, and the chemical
characterization of both compounds is listed below. N2-isopropyl-
N4-(2-(trifluoromethyl)benzyl)thieno[3,2-d]pyrimidine-2,4-diamine
(AWB124): 1Hnuclearmagnetic resonance (NMR) (400MHz, CDCl3)
d [parts per million (ppm)] 7.68 (d, J = 7.8 Hz, 1H), 7.61 (d, J = 7.8 Hz,
1H), 7.55 (d, J = 5.3 Hz, 1H), 7.50 (t, J = 7.6 Hz, 1H), 7.38 (t, J = 7.6 Hz,
1H), 7.11 (d, J = 5.3 Hz, 1H), 5.09 (br. s, 1H), 5.01 (d, J = 5.7 Hz, 2H),
4.79 (br. s, 1H), 4.20 to 4.06 (m, 1H), 1.18 (d, J = 6.5 Hz, 6H). 13C NMR
(101 MHz, CDCl3) d (ppm) 160.87, 157.68, 137.84, 132.58, 131.40,
131.02, 130.02, 128.52, 127.75, 126.39, 124.96, 124.29, 106.24, 43.39,
41.42, 23.44. High-resolution mass spectrometry (HRMS) (Cl)Johnston et al., Sci. Adv. 2017;3 : eaao1551 27 September 2017C17H18F3N4S [M+H]
+ 367.1196. For elemental (CHN) analysis,
C17H17F3N4S required the following: C, 55.73%; H, 4.68%; N, 15.29%;
found C, 55.64%; H, 4.71%; N, 15.33%.
N-((2-(trifluoromethyl)pyridin-3-yl)methyl)thieno[3,2-d]pyrimidin-
4-amine (AWG117): 1HNMR (400MHz, CDCl3) d (ppm) 8.58 (s, 1H),
8.54 (d, J = 4.3Hz, 1H), 7.99 (d, J = 7.9 Hz, 1H), 7.68 (d, J = 5.4 Hz, 1H),
7.39 (dd, J=10.1, 5.0Hz, 2H), 5.41 (d, J=5.2Hz, 1H), 5.05 (d, J=6.1Hz,
2H). 13C NMR (101 MHz, CDCl3) d (ppm) 160.21, 159.91, 156.94,
154.91, 147.89, 138.88, 133.22, 131.37, 126.64, 125.53, 123.96, 115.26,
40.17. HRMS (ES+) C130F3N4S [M+H]
+ 311.0575. For elemental
(CHN) analysis, C13H9F3N4S required the following: C, 50.32%; H,
2.92%; N 18.06%; found C, 50.41%; H, 2.88%; N, 18.10%.
In vitro Wolbachia cell-based screening assay
An A. albopictus cell line C6/36 (American Type Culture Collection
number CRL-1660) stably infected with Wolbachia pipientis wAlbB
[C6/36 (wAlbB)] was routinely cultured in Leibovitz’s L-15 medium
containing 2 mM L-glutamine, 1% nonessential amino acids, 2% tryp-
tose phosphate broth (Sigma-Aldrich), and 5% heat-inactivated fetal
calf serum (Cambrex Bio Science) at 26°C (51). A C6/36 (wAlbB)
cell-based assay developed to screen drugs/compounds active against
Wolbachia in vitro was used as previously described (52), with a few
modifications. Briefly, 24 hours before use, compound plates were
thawed for at least 2 hours at room temperature, with rocking. Plates
were centrifuged briefly (less than 30 s) to remove drops from the
underside of the seal. Daughter plates were prepared from the master
plates by transferring 10 ml into new plates, and these were stored at
4°C until the following day. C6/36 (wAlbB) cells, subcultured 24 hours
previously, were seeded at 10,000 cells per well in 96-well flat-bottom
sterile culture plates. Compounds from the daughter plates were di-
luted to the appropriate working concentration in culture medium and
added to test wells, and cells were cultured in a total volume of 200 ml at
26°C for 9 days. The final concentration of each compound used was
2.5mgml−1. Vehicle (DMSO)–treatedmediumanddoxycycline at a con-
centration of 8 mM were used as negative and positive controls, respec-
tively, and were included on each test plate. Compounds and controls
were added in triplicate within plates (that is, compounds fromone plate
were spread over three reciprocal cell plates, with 18 compounds per
plate). At the end of the screening assay, cytotoxicity was scored using
microscopy (medium toxicity was determined as approximately 50% or
greater reduction in cell confluence in comparison to theDMSOcontrol,
and high toxicity was determined as approximately 90% or greater
reduction in confluence), and samples were collected bywashing adher-
ent cells once in sterile Dulbecco’s phosphate-buffered saline (Sigma-
Aldrich) and adding 150 ml of Wizard SV Lysis Buffer (Promega) for
genomic DNA (gDNA) extraction.
DNA isolation and qPCR
gDNAwas extracted from C6/36 (wAlbB) cell lysates using theWizard
SV 96 Genomic DNA Purification System (Promega), according to the
manufacturer’s instructions, and eluted in 100 ml of water. Quantifica-
tion of the ribosomal geneW. pipientis 16Swas performed as previously
described (53), with modifications. Briefly, qPCR was performed on a
C1000 thermocycler with a CFX384 Real-Time System (Bio-Rad Lab-
oratories Ltd) under the following conditions: 95°C for 3 min, 40 cycles
of 95°C for 10 s, and 55°C for 30 s. qPCRs were performed in 10 ml of
SsoFast EvaGreen (Bio-Rad) reactions containing 2 ml of gDNA, 0.4 mM
concentrationof each primer in 1× SsoFast EvaGreen Supermix (Bio-Rad).
Quantification was calculated by reference to a linear standard curve7 of 10
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 of log10-diluted (5 × 10
6 to 5 × 100) full-length amplicons synthesized
as single-stranded oligonucleotides (Sigma-Genosys).
Quality control
The quality of individual assays was assessed by calculating Z and Z′
statistical parameters using the data generated by control wells (54).
Data from assays that did not achieve Z′ factors of 0.4 or above were
rejected, and the compounds were retested. A typical primary screening
run is shown in Fig. 1 and described in further detail in Supplementary
Materials and Methods.
Hit confirmation
Compounds that reduced theWolbachia 16S copy number by 1 log or
greater were cherry-picked from the daughter plates and tested again
to confirm the activity. Those that again achieved a log reduction in
Wolbachia 16S copy numbers of 1 log or greater were considered con-
firmed hits.
Validation with dry stocks
Compounds were purchased from eMolecules and dissolved in DMSO
before use. Working dilutions were prepared using appropriate molar
concentrations, and cell-based assays, with a qPCR readout, were con-
ducted using the methods described above. Each compound was tested
at a standard concentration of 5 mM. Duplicate plates were prepared
and used to quantify cytotoxicity in a CellTiter-Glo Luminescent Cell
Viability Assay (Promega), according to the manufacturer’s instruc-
tions. The level of cytotoxicity for each compound was determined by
comparing the CellTiter-Glo luminescence readout against the vehicle-
treated control wells, with compounds that reduced the percentage lu-
minescence by 30% or greater being classed as cytotoxic.
Selected hits were set up in dose response using a recently validated
higher-throughput screen developed by A∙WOL (37). While using
the same cell line, this assay uses a high-content imaging platform
(Operetta, PerkinElmer) to quantify the percentage of cells infected
with Wolbachia after treatment. Using the methods described by
Clare et al. (37), selected compounds were incubated with cells in
a dose range from 5 to 19.5 nM to generate dose-response curves
and EC50 values.
Chemoinformatics
Compounds were provided as SMILES (simplified molecular-input
line-entry system) strings, and ADMET predictions were made using
StarDrop (55). Molecular properties and Pareto analysis were cal-
culated using BIOVIA Pipeline Pilot (56). Molecular fingerprints
and PCA were performed using DataWarrior (31). The PathFp de-
scriptor encodes all distinct linear strands of up to seven atoms with-
in amolecule. The PathFp descriptor is related to the folded Daylight
fingerprint (57).SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/3/9/eaao1551/DC1
Supplementary Materials and Methods
fig. S1. Box plots of the molecular properties of the 10,000 compounds screened and whether
they were validated hits (≥1 log drop).
table S1. Properties assessed to identify chemotypes for medicinal chemistry optimization.
scheme S1. Synthetic route for AWB124.
scheme S2. Synthetic route for AWG117.
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